Group 1 - The core idea of the research is to identify environmental factors that accelerate biological aging, revealing that smoking, cadmium, and lead are significant contributors to accelerated aging [1][7][13]. - The study utilized two main research tools: exposome analysis and epigenetic clocks to assess the relationship between environmental chemicals and aging [4][5][6]. Group 2 - The exposome encompasses all environmental exposures from conception to death, influencing gene expression and aging speed [4]. - The epigenetic clocks measure biological age and health risks, with the second generation predicting health risks and the third generation measuring the speed of aging [5][6]. Group 3 - High levels of cotinine, a marker for tobacco exposure, correlate with increased biological aging, with each standard deviation increase in cotinine accelerating the death risk clock by 1.40 years [10][11]. - Cadmium is identified as the primary environmental factor accelerating biological aging, with each standard deviation increase in serum cadmium leading to significant increases in both death risk clocks [14][16]. Group 4 - Lead exposure is linked to accelerated aging, with each standard deviation increase in blood lead levels resulting in notable increases in death risk clocks [20][21]. - Interestingly, exposure to certain toxic chemicals like dioxins and PCBs was found to correlate with a decrease in epigenetic aging, suggesting a complex relationship between exposure and biological age [22][23]. Group 5 - The study highlights the importance of socioeconomic status and dietary choices in influencing aging speed, with higher income and better food choices associated with slower biological aging [26][27]. - The findings suggest that individuals can manage their aging process by making informed lifestyle choices, such as quitting smoking and diversifying their diet [28][29].

Core Viewpoint - Aimeike Technology Development Co., Ltd. reported a decline in revenue and net profit for Q1 2025, indicating challenges in the medical aesthetics industry amid increased competition and regulatory pressures [1][2]. Financial Performance - In Q1 2025, Aimeike achieved revenue of 663 million yuan, a year-on-year decrease of 17.90% - The net profit attributable to shareholders was 444 million yuan, down 15.87% year-on-year [1]. Market Trends - The non-surgical light medical aesthetics market is expected to grow at a rate of 10% in 2024, down from previous highs in 2023, as the industry transitions from "technical dividends" to "comprehensive competitiveness" [2]. - Increased competition has led to a downward trend in product prices, while consumer decision-making periods for high-end medical aesthetics have lengthened due to macroeconomic uncertainties [2]. Strategic Positioning - Aimeike is one of the few leading companies not actively participating in price wars, maintaining a gross margin of 93.85% in Q1 2025, a slight decrease of 0.7 percentage points year-on-year [4]. - The company emphasizes brand value and product quality over short-term price advantages, aiming for long-term market resilience [4]. Research and Development - Aimeike's R&D expenses reached 58.54 million yuan in Q1 2025, accounting for 8.82% of revenue, an increase of 1.65% year-on-year, reflecting a strong commitment to innovation [4]. - Ongoing projects focus on cutting-edge areas such as regenerative materials and collagen, which may not yield immediate sales but are expected to drive long-term growth [4]. Product Expansion - Aimeike has received approval for a new product, a medical-grade gel for jawline filling, which will soon be launched, marking it as the third approved product in this category in China [5]. - The company is also expanding its market presence through the acquisition of 85% of South Korea's REGEN Biotech Inc. for approximately 190 million USD, positioning itself as the only domestic company with two regenerative medical aesthetics products [5].